scholarly journals Differentiating uterine sarcoma from leiomyoma: BET1T2ER Check!

2021 ◽  
pp. 20201332
Author(s):  
Janette Smith ◽  
Jeries Paolo Zawaideh ◽  
Hilal Sahin ◽  
Susan Freeman ◽  
Helen Bolton ◽  
...  
Keyword(s):  
Current Literature ◽  
Signal Intensity ◽  
Uterine Sarcoma ◽  
Imaging Features ◽  
Benign Lesions ◽  
Uterine Sarcomas ◽  
Secondary Spread ◽  
Key Features

Although rare, uterine sarcoma is a diagnosis that no one wants to miss. Often benign leiomyomas (fibroids) and uterine sarcomas can be differentiated due to the typical low T2 signal intensity contents and well-defined appearances of benign leiomyomas compared to the suspicious appearances of sarcomas presenting as large uterine masses with irregular outlines and intermediate T2 signal intensity together with possible features of secondary spread. The problem is when these benign lesions are atypical causing suspicious imaging features. This article provides a review of the current literature on imaging features of atypical fibroids and uterine sarcomas with an aide-memoire BET1T2ER Check! to help identify key features more suggestive of a uterine sarcoma.

scholarly journals Imaging Features of Aggressive Giant Cell Tumors of the Mobile Spine: Retrospective Analysis of 101 Patients From Single Center

2021 ◽  
pp. 219256822098228
Author(s):  
Bei Yuan ◽  
Lihua Zhang ◽  
Shaomin Yang ◽  
Hanqiang Ouyang ◽  
Songbo Han ◽  
...  
Keyword(s):  
Giant Cell ◽  
Vertebral Body ◽  
Signal Intensity ◽  
Imaging Features ◽  
Single Center ◽  
Giant Cell Tumors ◽  
Ct Guided ◽  
Cortical Destruction ◽  
Mobile Spine ◽  
T2 Weighted Images

Study Design: Retrospective study. Objectives: Giant cell tumors (GCTs) of the mobile spine can be locally aggressive. This study described and classified the typical and atypical appearance of aggressive spinal GCTs according to imaging findings to help the imaging diagnosis, especially for patients with rapid neurological deficit that may require emergent surgery without biopsy. Methods: Computed tomography (CT) and magnetic resonance imaging (MRI) scans of patients diagnosed with aggressive spinal GCTs at single center were reviewed. Results: Overall, 101 patients with 100 CT images and 94 MR images were examined. All lesions were osteolytic with cortical destruction; 95 lesions showed epidural extension; 90 were centered in the vertebral body; 82 showed pathological fracture and/or collapse of the vertebral body; 78 had pseudotrabeculation on CT; 80 showed low-to-iso signal intensity or heterogeneous high-signal intensity with cystic areas on the T2-weighted images; 9 showed fluid–fluid level on T2-weighted images; and 61 patients showed marked enhancement on contrast-enhanced CT and/or MRI. Forty-one lesions (40.6%) had at least 1 atypical radiographic feature: 19 involved ≥2 segments; 11 were centered in the posterior neural arch; 10 had a paravertebral mass over 2 segments; 16 showed partial margin sclerosis with partial cortical destruction on CT scans; and 3 showed mineralization within the tumor on CT. Eighty-eight patients underwent CT-guided biopsy with a diagnostic accuracy rate of 94.3%. Conclusions: Spinal GCTs might appear more radiologically atypical, and about 40% of the lesions may have at least 1 atypical feature. CT-guided biopsies are recommended for definitive diagnosis.

Uterine Leiomyoma or Sarcoma?

2021 ◽  
pp. 289-304
Author(s):  
Theodoros Theodoridis ◽  
Dimitra Aivazi ◽  
Leonidas Zepiridis ◽  
Nikolaos Vlachos
Keyword(s):  
Differential Diagnosis ◽  
Smooth Muscle ◽  
Connective Tissue ◽  
Muscle Cells ◽  
Uterine Sarcoma ◽  
Current Evidence ◽  
Optimal Management ◽  
Benign Neoplasms ◽  
Uterine Sarcomas ◽  
Epithelial Neoplasms

Uterine leiomyomas are benign neoplasms derived from the smooth muscle cells of the myometrium. In contrast, uterine sarcomas are rare tumors, with a prevalence of 3-7 per 100,000 women, originating from myometrial cells or endometrial connective tissue. Uterine sarcomas and especially leiomyosarcomas are more aggressive than uterine epithelial neoplasms. The differential diagnosis between leiomyoma and uterine sarcoma preoperatively remains challenging for the clinical practitioner in order to determine optimal treatment. The chapter aims to summarize current evidence regarding differential diagnosis and optimal management of these two challenging clinical entities.

scholarly journals Primary Lymphangioma of the Palatine Tonsil in a 9-Year-Old Boy: A Case Presentation and Literature Review

2016 ◽  
Vol 2016 ◽  
pp. 1-3
Author(s):  
Eleftheria Iliadou ◽  
Nektarios Papapetropoulos ◽  
Eleftherios Karamatzanis ◽  
Panagiotis Saravakos ◽  
Konstantinos Saravakos
Keyword(s):  
Literature Review ◽  
Histological Examination ◽  
Current Literature ◽  
Short Review ◽  
Clinical Suspicion ◽  
Palatine Tonsil ◽  
Benign Lesions ◽  
Case Presentation ◽  
The Right ◽  
Made In

Primary lymphangiomas or lymphangiomatous polyps of the palatine tonsil are rare benign lesions that are described infrequently in the literature. The majority of the published cases concern adults. We report a case of a lymphangiomatous lesion of the right palatine tonsil of a 9-year-old boy. Our clinical suspicion was confirmed by the histological examination after tonsillectomy and the diagnosis of primary lymphangioma of the tonsil was made. In this case we discuss the clinical and histopathological features of this lesion and present a short review of the current literature.

Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas: Report on Five Patients and a Review of the Literature

2009 ◽  
Vol 19 (2) ◽  
pp. 245-248 ◽  
Author(s):  
Frédéric Amant ◽  
An Coosemans ◽  
Vincent Renard ◽  
Els Everaert ◽  
Ignace Vergote
Keyword(s):  
Clinical Benefit ◽  
Response Rate ◽  
Uterine Sarcoma ◽  
Current Data ◽  
Clinical Impact ◽  
High Grade ◽  
Review Of The Literature ◽  
Uterine Sarcomas ◽  
Previously Treated ◽  
Undifferentiated Uterine Sarcoma

AbstractThe clinical impact of ET-743 (trabectedin; Yondelis) in women with leiomyosarcoma and undifferentiated uterine sarcoma in patients previously treated with chemotherapy is investigated. Current data show a clinical benefit in 2/5 patients, of which 1 had a partial remission during 9 months. Pooling the treatment outcomes with literature data, a response in 5 (38%) of 13 patients and a clinical benefit in 7 (54%) of 13 patients for all high-grade uterine sarcomas is calculated. When only uterine leiomyosarcomas are concerned, response rate is 5 (45%) of 11 patients with a clinical benefit in 7 (64%) of 11 patients. These results on the use of ET-743 in uterine sarcoma patients support the conductance of larger trials.

Non-puerperal uterine inversion in association with uterine sarcoma: clinical management

2003 ◽  
Vol 13 (2) ◽  
pp. 244-245 ◽  
Author(s):  
M. Moodley ◽  
J. Moodley
Keyword(s):  
Surgical Procedures ◽  
Clinical Management ◽  
Vaginal Discharge ◽  
Uterine Sarcoma ◽  
Rare Entity ◽  
Vaginal Route ◽  
Uterine Sarcomas ◽  
Vaginal Mass ◽  
Uterine Inversion ◽  
Abdominal Route

Non-puerperal uterine inversion due to uterine sarcoma is a rare entity often diagnosed at the time of surgery. Patients may present with pelvic pain, vaginal discharge, or hemodynamic shock. Clinically, the diagnosis may be suspected if there is a large vaginal mass and difficulty in palpating the cervix. Four surgical procedures have been described to manage non-puerperal uterine inversion, two by the abdominal route and two by the vaginal route. The Haultain procedure performed abdominally is preferred for uterine sarcomas as it facilitates reversion of the uterus vaginally or excision of the pedicle and removal of the prolapsed tumor vaginally. We describe a patient with this condition managed by the Haultain procedure.

Uterine Sarcomas: Histology and Its Implications on Therapy

2012 ◽  
pp. 356-361 ◽  
Author(s):  
Martee L. Hensley
Keyword(s):  
High Risk ◽  
Metastatic Disease ◽  
Objective Response ◽  
The United States ◽  
Good Prognosis ◽  
Uterine Sarcoma ◽  
Low Grade ◽  
High Grade ◽  
Limited Disease ◽  
Uterine Sarcomas

Overview: Uterine sarcomas are rare cancers, they comprise only 5% of all uterine malignancies. There are about 2,000 cases of uterine sarcoma diagnosed annually in the United States. Uterine sarcomas may be categorized as either favorable-risk, low-grade malignancies with a relatively good prognosis or as poor-risk, high-grade cancers that carry a high risk for tumor recurrence and disease progression. Expert histologic review is critical for appropriate diagnosis and management. Uterine sarcoma histologies considered to carry a more favorable prognosis include low-grade endometrial stromal sarcomas and adenosarcomas. The high-grade sarcomas include high-grade leiomyosarcomas, high-grade undifferentiated endometrial sarcomas, and adenosarcomas with sarcomatous overgrowth. The favorable histology, low-grade uterine sarcomas may be cured with surgical resection of uterus-limited disease. These tumors are often hormone-sensitive, and treatment with hormonal therapies may be efficacious for patients with advanced, unresectable disease. High-grade uterine leiomyosarcomas and undifferentiated endometrial sarcomas carry a high risk for recurrence, even after complete resection of uterus-limited disease. No adjuvant intervention has been shown to improve survival outcomes. Advanced, metastatic disease is generally treated with systemic cytotoxic therapies, which may result in objective response but is not curative. Selected patients with isolated metastatic disease and a long disease-free interval may benefit from metastatectomy.

scholarly journals Different Subtypes of Uterine Sarcoma Require a Separate Therapeutic Approach

2005 ◽  
Vol 1 (3) ◽  
pp. 375-383
Author(s):  
Frederic Amant
Keyword(s):  
Tumor Biology ◽  
Clinical Importance ◽  
Careful Analysis ◽  
Uterine Sarcoma ◽  
Treatment Modalities ◽  
Molecular Characteristics ◽  
Uterine Sarcomas ◽  
Collective Data ◽  
Hormone Sensitive ◽  
Insight Into

Uterine sarcomas include a variety of mono- and biphasic malignancies, whereas tumor biology varies from an indolent and hormone-sensitive growth pattern to an aggressive and nonresponsive disease that is inevitably fatal. Insight into these different entities has only been gained after careful analysis of clinical, pathologic and molecular characteristics during the last few years. Furthermore, the rarity of uterine sarcomas has motivated many to collect data from different subtypes and to report on the collective data in order to report on larger numbers. The current overview aims to provide insights of clinical importance into each type of uterine sarcoma, with a special emphasis on treatment modalities.

Sign in / Sign up

Export Citation Format

Share Document